Skip to main content
. 2021 Aug 24;19(7):1047–1060. doi: 10.20892/j.issn.2095-3941.2020.0416

Figure 4.

Figure 4

In vivo biodistribution studies of lung adenocarcinoma NCI-H889 tumor-bearing athymic nude mice treated with UCNP-siRNA-PAA-AS1411 nanocages. (A) Live in vivo bioimaging of NCI-H889 tumor-bearing athymic nude mice 1 and 4 h after inhalation with 1 mL of 1 mg/mL UCNP-siRNA-PAA-AS1411 nanocages. (B) Quantitative biodistribution of UCNP-siRNA and UCNP-siRNA-PAA-AS1411 nanoparticles in lung tumors and organs based on the region of interest analysis of the mean fluorescence intensity of each organ; (C) Quantification of UCNP distribution in organs by inductively-coupled plasma mass spectrometry. The UCNP-siRNA-PAA-AS1411 and UCNP-siRNA distributions in the liver, spleen, lung (tumor), kidney, and heart at 4 h after the inhalation-mediated localized delivery of UCNP-siRNA-PAA-AS1411/UCNP-siRNA nanocages. UCNP nanocage fluorescence: λexcitation = 980 nm, λemission = 801 ± 20 nm; tdTomato-labeled tumor fluorescence: λexcitation = 554 nm, λemission = 581 ± 20 nm; the SD (error bars) in b and c were calculated based on 6 animals (n = 6; ***P < 0.005; **P < 0.01) in each study group.